About

Management

Ascelia Pharma has an experienced management team:

Magnus Corfitzen

Magnus Corfitzen 

Born 1975. Chief Executive Officer since 2014.

Professional background
Magnus Corfitzen has extensive experience from investing, building and growing Life Science companies in various roles including operational activities or investment responsibilities for public and private biotech and medtech companies. Magnus Corfitzen also has board experience from a number of Life Science companies. Magnus Corfitzen has previously inter alia been Investment Director at Sunstone Capital A/S and Investment Director at Vækstfonden (the Danish Growth Fund).

Education
M.Sc. in Mathematical Economics from the University of Aarhus, Denmark, which included studies at Harvard University, US.



Dorthe da Graça Thrige

Dorthe da Graça Thrige 

Born 1967. Chief Operating Officer since 2014.

Professional background
Dorthe da Graça Thrige has extensive experience in R&D and executive management at leading Swedish and Danish biotech and pharma companies. Dorthe da Graça Thrige has previous experience from inter alia various positions at Active Biotech AB, including Director of Development, Head of Project Management and Head of Drug Discovery and Research Scientist at AstraZeneca.    
           
Education
M.Sc. in Pharmaceutical Sciences and Ph.D. in Structural Medicinal Chemistry from University of Copenhagen, Denmark.



Jonas Hink

Jonas Hink 

Born 1969. Chief Medical Officer since 2014.

Professional background
Jonas Hink has extensive experience from several R&D and commercial positions in listed biotech, diagnostic and pharma companies. Jonas Hink has previously inter alia been Clinical Director at DAKO/Agilent Techologies, Managing Director and Senior Consultant at Biopharm Forward ApS and Scientific Director at Novo Nordisk.

Education
M.D. and Ph.D. from University of Copenhagen, Denmark. MBA from Copenhagen Business School, Denmark.


Kristian Borbos

Kristian Borbos 

Born 1978. Chief Financial Officer since 2017.

Professional background
Kristian Borbos has extensive banking and finance experience from large listed companies as Sell-side Analyst and other advisory roles in banking to various financial positions in large corporates including treasury, financial reporting and planning and IR activities. Kristian Borbos has previously inter alia been Business Finance Manager at Novozymes and Lead Investor Relations Manager at DONG Energy and senior analyst at Danske Bank and Danske Markets.

Education
M.Sc. in Business Administration from Lund University, Sweden.